---
memory_schema: 2
active_objective: Close the F.6.2.Fix.4 presentation-only rerender review
current_work_item: Obtain and review the fresh F.6.2.Fix.4 rerender bundle
active_status: ACTIVE
next_action: User supplies the fresh F.6.2.Fix.4 rerender bundle for review
baseline_commit: 012954d449735b047f453f288641d26c7cef2f8f
source_commit: b929815517643edaa75949f7e61ce46c6e8f0d63
bundle_profile_commit: c3252f1ec43dcca0357aebe8c6ca75d7d198f99a
---
# Current KaonLT handoff

## Resume Identity

- Repository: `trottar/lt_analysis`; branch: `test`.
- Recheck `git status --short --branch`, `git rev-parse HEAD`, and the active
  frontmatter before work. The M.2 source-review baseline is
  `012954d449735b047f453f288641d26c7cef2f8f`.
- F.6.2.Fix.4 presentation source:
  `b929815517643edaa75949f7e61ce46c6e8f0d63`.
- F.6.2 clean bundle/profile commit:
  `c3252f1ec43dcca0357aebe8c6ca75d7d198f99a`.

## Current Gate

F.6.2 scientific validation is CLOSED / RUNTIME VALIDATED; see the
[scientific closure record](../evidence/f6-2-scientific-runtime-closure.md).
F.6.2 overall is ACTIVE because F.6.2.Fix.4 is DEVELOPMENT COMPLETE, FARM
VALIDATION PENDING. The accepted F.6.2 scientific JSON and fingerprints are
frozen for the presentation-only rerender.

## Farm-only Boundary

The user performs the narrow `tcsh` farm step. Codex does not commit, push,
initiate farm execution, or claim runtime validation. For a bundle-only step,
use the [farm procedure](../decisions/farm-validation-bundle-procedure.md),
the reviewed clean worktree when provenance requires it, and do not regenerate
the accepted scientific JSON.

## Next Action

Obtain and review the fresh F.6.2.Fix.4 rerender bundle. Verify its manifest,
source provenance, presentation PDF, and exact continuity of the accepted
F.6.2 JSON SHA-256, artifact fingerprint, and validation fingerprint.

## Downstream State

E.8 remains BLOCKED until F.6.2 overall closes. F.6.3 remains BLOCKED pending
accepted F.6.2 plus E.8; F.6.4 remains BLOCKED pending F.6.2/F.6.3 evidence.
The accepted yield is still the baseline, Method B remains diagnostic only,
and no Method-A production promotion is authorized.
